Drugs / EMB-15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07607054 | May 2026 → May 2029 expected | — | Shanghai EpimAb Biotherapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMB-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07607054 ↗ |
| Target | ALPG | “against ALPP/ALPG and CD3” NCT07607054 ↗ |
| Target | ALPP | “against ALPP/ALPG and CD3” NCT07607054 ↗ |